Bullous mycosis fungoides with large cell transformation: a fatal outcome following brentuximab treatment
European Journal of Dermatology · 2023
DOI: 10.1684/ejd.2023.4569 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Dermatology, 2023. Verfasst von Lanyu Sun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Serviço de Dermatologia, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal. Hauptthemen laut MEDLINE: Mycosis Fungoides, Skin Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Serviço de Dermatologia, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.
- Serviço de Dermatologia, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal, Clínica Universitária de Dermatologia, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal,…
- Unidade de Dermatologia, Fundação Champalimaud, Lisbon, Portugal.
Zitieren
APA
Sun, L., Alpalhão, M., Duarte, S., De Vasconcelos, P., Sanches, M., De-Almeida, L. S., & Filipe, P. (2023). Bullous mycosis fungoides with large cell transformation: a fatal outcome following brentuximab treatment. European Journal of Dermatology. https://doi.org/10.1684/ejd.2023.4569
Vancouver
Sun L, Alpalhão M, Duarte S, De Vasconcelos P, Sanches M, De-Almeida LS, et al. Bullous mycosis fungoides with large cell transformation: a fatal outcome following brentuximab treatment. European Journal of Dermatology. 2023. doi:10.1684/ejd.2023.4569
BibTeX
@article{Sun2023,
author = {Sun, Lanyu and Alpalhão, Miguel and Duarte, Sofia and De Vasconcelos, Pedro and Sanches, Maria and De-Almeida, Luís Soares and Filipe, Paulo},
title = {Bullous mycosis fungoides with large cell transformation: a fatal outcome following brentuximab treatment},
journal = {European Journal of Dermatology},
year = {2023},
doi = {10.1684/ejd.2023.4569}
}
EUVIMED